BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day

Core Insights - AtaiBeckley Inc. is advancing its clinical-stage biotechnology efforts, particularly focusing on BPL-003, a nasal spray for treatment-resistant depression (TRD), with plans to initiate Phase 3 studies in Q2 2026 following a successful End-of-Phase 2 meeting with the FDA [1][4][5] Clinical Development - BPL-003 has received Breakthrough Therapy Designation and has shown positive Phase 2b results, indicating rapid antidepressant effects by Day 2 and sustained improvements for up to eight weeks [2][8] - The upcoming Phase 3 studies, ReConnection-1 and ReConnection-2, will consist of a 12-week randomized, double-blind, placebo-controlled core study, followed by a 52-week open-label extension [4][5] Financial and Operational Readiness - The company has reaffirmed its cash runway extending into early 2029, ensuring financial stability for ongoing and future clinical trials [3][7] - AtaiBeckley is advancing its commercial readiness strategy for BPL-003, aiming to integrate the treatment into existing psychiatric workflows without the need for in-session psychotherapy [5][6] Pipeline Progress - The company is also making progress with other pipeline candidates, including positive Phase 2a results for EMP-01 and anticipates topline data for VLS-01 in H2 2026 [3][7] Expert Perspectives - Discussions during the Investor Day highlighted the importance of streamlined treatment experiences and the potential for BPL-003 to expand patient access while maintaining clinical efficacy [9][10]